Differential regulation of a fibroblast growth factor-binding protein by receptor-selective analogs of retinoic acid

被引:9
作者
Boyle, BJ
Harris, VK
Liaudet-Coopman, EDE
Riegel, AT
Wellstein, A
机构
[1] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA
[2] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, Washington, DC 20007 USA
关键词
FGF-BP; FGF; retinoids; RXR; RAR; angiogenesis;
D O I
10.1016/S0006-2952(00)00507-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We have demonstrated earlier that a secreted fibroblast growth factor-binding protein (FGF-BP) can enhance angiogenesis and promote tumor growth in vivo. Furthermore, we found that FGF-BP expression in squamous cell carcinoma (SCC) is reduced by concentrations of retinoids that are effective in the treatment of SCC and that this repression can occur at the transcriptional and post-transcriptional level. To further examine the mechanism of regulation of FGF-BP by retinoids and the role played by retinoid receptor subtypes, we utilized retinoic acid receptor (RAR)-selective (TTNPB) and retinoid X receptor (RXR)-selective (LG100268) ligands. In ME-180 SCC cells, FGF-BP mRNA was down-regulated by TTNPB with an IC50 value of 1 nM, whereas transcription was only repressed at 10,000-fold higher concentrations (IC50 > 10 muM) This suggests that the major effects of retinoids on FGF-BP occur at the post-transcriptional level. In four additional SCC cell lines, FGF-BP was also down-regulated by TTNPB with IC50 values of less than or equal to 1 nM, demonstrating that RAR receptors can modulate FGF-BP mRNA levels very effectively in SCC cells. The IUCR-selective ligand on its own was only effective in two of the five cell lines (IC50 of approximate to 1 nM). In all of the SCC cell lines, a low concentration of RAR sensitized FGF-BP mRNA to treatment with the RXR ligand and the combination of the RXR and RAR ligands enhanced the efficacy beyond that of the individual ligands. We conclude that RAR receptors are major regulators of FGF-BP mRNA at the post-transcriptional level and propose that an RAR-induced gene product mediates the RXR effects on FGF-BP mRNA. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1677 / 1684
页数:8
相关论文
共 29 条
[1]   DESIGN AND SYNTHESIS OF POTENT RETINOID-X RECEPTOR-SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA-CELLS [J].
BOEHM, MF ;
ZHANG, L ;
ZHI, L ;
MCCLURG, MR ;
BERGER, E ;
WAGONER, M ;
MAIS, DE ;
SUTO, CM ;
DAVIES, PJA ;
HEYMAN, RA ;
NADZAN, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3146-3155
[2]   A decade of molecular biology of retinoic acid receptors [J].
Chambon, P .
FASEB JOURNAL, 1996, 10 (09) :940-954
[3]   A secreted FGF-binding protein can serve as the angiogenic switch in human cancer [J].
Czubayko, F ;
LiaudetCoopman, EDE ;
Aigner, A ;
Tuveson, AT ;
Berchem, GJ ;
Wellstein, A .
NATURE MEDICINE, 1997, 3 (10) :1137-1140
[4]  
CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243
[5]   ACTIVE CANCER-THERAPY COMBINING 13-CIS-RETINOIC ACID WITH INTERFERON-ALPHA [J].
DMITROVSKY, E ;
BOSL, GJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (04) :218-219
[6]  
Gottardis MM, 1996, CANCER RES, V56, P5566
[7]   Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements [J].
Harris, VK ;
Liaudet-Coopman, EDE ;
Boyle, BJ ;
Wellstein, A ;
Riegel, AT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (30) :19130-19139
[8]   A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors [J].
Kamei, Y ;
Xu, L ;
Heinzel, T ;
Torchia, J ;
Kurokawa, R ;
Gloss, B ;
Lin, SC ;
Heyman, RA ;
Rose, DW ;
Glass, CK ;
Rosenfeld, MG .
CELL, 1996, 85 (03) :403-414
[9]   Molecular epidemiology and retinoid chemoprevention of head and neck cancer [J].
Khuri, FR ;
Lippman, SM ;
Spitz, MR ;
Lotan, R ;
Hong, WK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) :199-211
[10]   Effect of 13-cis-retinoic acid with neoadjuvant chemotherapy in patients with squamous cervical carcinoma [J].
Kim, JW ;
Kim, YT ;
Choi, SM ;
Kim, DK ;
Song, CH .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05) :442-444